Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice

Vaccine

Volumn 29, Issue 16, 2011, Pages 2910-2917

  Naarding, Marloes A ^a   Falkowska, Emilia ^a   Xiao, Hui ^a   Dragic, Tatjana ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvants; E2 glycoprotein; Hepatitis C virus; Neutralizing antibodies

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; GLYCOPROTEIN E2; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; QUILA SAPONIN; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; FEMALE; GALACTOSYLCERAMIDES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; SAPONINS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 79953216363     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.009     Document Type: Article

References (70)

1. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000, 20(1):17-35.
2. Tillmann H.L., Manns M.P., Rudolph K.L. Merging models of hepatitis C virus pathogenesis. Semin Liver Dis 2005, 25(February (1)):84-92.
3. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996, 93(5):1759-1763.
4. Keck Z.Y., Op De Beeck A., Hadlock K.G., Xia J., Li T.K., Dubuisson J., et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 2004, 78(September (17)):9224-9232.
5. Keck Z.Y., Xia J., Cai Z., Li T.K., Owsianka A.M., Patel A.H., et al. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 2007, 81(January (2)):1043-1047.
6. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004, 101(July (27)):10149-10154.
7. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79(May (10)):6023-6034.
8. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 2002, 359(April (9316)):1478-1483.
9. Puig M., Major M.E., Mihalik K., Feinstone S.M. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2004, 22(February (8)):991-1000.
10. Abrignani S., Houghton M., Hsu H.H. Perspectives for a vaccine against hepatitis C virus. J Hepatol 1999, 31(Suppl. 1):259-263.
11. Esumi M., Rikihisa T., Nishimura S., Goto J., Mizuno K., Zhou Y.H., et al. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch Virol 1999, 144(5):973-980.
12. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994, 91(February (4)):1294-1298.
13. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 2010, 128(January (1)):29-35.
14. Krishnan J., Lee G., Choi S. Drugs targeting Toll-like receptors. Arch Pharm Res 2009, 32(November (11)):1485-1502.
15. Warshakoon H.J., Hood J.D., Kimbrell M.R., Malladi S., Wu W.Y., Shukla N.M., et al. Potential adjuvantic properties of innate immune stimuli. Hum Vaccin 2009, 5(June (6)):381-394.
16. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003, 171(November (10)):5140-5147.
17. Morshed S.R., Takahashi T., Savage P.B., Kambham N., Strober S. Beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. Clin Immunol 2009, 132(September (3)):321-333.
18. Liu K., Idoyaga J., Charalambous A., Fujii S., Bonito A., Mordoh J., et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 2005, 202(December (11)):1507-1516.
19. Kim H.Y., Kim H.J., Min H.S., Kim S., Park W.S., Park S.H., et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med 2005, 201(January (1)):41-47.
20. Trobonjaca Z., Kroger A., Stober D., Leithauser F., Moller P., Hauser H., et al. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 2002, 168(April (8)):3763-3770.
21. Benko S., Magyarics Z., Szabo A., Rajnavolgyi E. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol Chem 2008, 389(May (5)):469-485.
22. Kong N.C., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008, 73(April (7)):856-862.
23. Schwarz T.F. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine. Cervarix. Adv Ther 2009, 26(November (11)):983-998.
24. Falkowska E., Kajumo F., Garcia E., Reinus J., Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry. CD81 binding, and neutralization. J Virol 2007, 81(August (15)):8072-8079.
25. Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y.S., et al. Formation of native hepatitis C virus glycoprotein complexes. J Virol 1997, 71(January (1)):697-704.
26. Patel A.H., Wood J., Penin F., Dubuisson J., McKeating J.A. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 2000, 81(Pt 12):2873-2883.
27. Dubuisson J., Hsu H.H., Cheung R.C., Greenberg H.B., Russell D.G., Rice C.M. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 1994, 68(10):6147-6160.
28. Cormier E.G., Tsamis F., Kajumo F., Durso R.J., Gardner J.P., Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 2004, 101(May (19)):7270-7274.
29. Meertens L., Bertaux C., Cukierman L., Cormier E., Lavillette D., Cosset F.L., et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008, 82(April (7)):3555-3560.
30. Lee K.J., Suh Y.A., Cho Y.G., Cho Y.S., Ha G.W., Chung K.H., et al. Hepatitis C virus E2 protein purified from mammalian cells is frequently recognized by E2-specific antibodies in patient sera. J Biol Chem 1997, 272(November (48)):30040-30046.
31. Lucas M., Tsitoura E., Montoya M., Laliotou B., Aslanoglou E., Kouvatsis V., et al. Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus. J Gen Virol 2003, 84(March (Pt 3)):545-554.
32. Flint M., Dubuisson J., Maidens C., Harrop R., Guile G.R., Borrow P., et al. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol 2000, 74(January (2)):702-709.
33. Roepstorff P. MALDI-TOF mass spectrometry in protein chemistry. EXS 2000, 88:81-97.
34. Houghton M., Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436(August (7053)):961-966.
35. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455(October (7213)):613-619.
36. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007, 17(January-February (1)):5-34.
37. Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 2001, 260:171-190.
38. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., Strikas R.A. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(July (RR-10)):1-42.
39. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142(March (5)):333-341.
40. Beasley R.P., Hwang L.Y. Immunogenicity of hepatitis B virus vaccine (Heptavax-B)-response of healthy adults. West J Med 1984, 140(May (5)):731-734.
41. Ault K.A. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Obstet Gynecol Surv 2006, 61(June (6 Suppl. 1)):S26-S31.
42. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 1991, 146(January (2)):431-437.
43. Newman M.J., Wu J.Y., Gardner B.H., Munroe K.J., Leombruno D., Recchia J., et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol 1992, 148(April (8)):2357-2362.
44. Freund J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization, a review. Am J Clin Pathol 1951, 21(July (7)):645-656.
45. Jennings V.M. Review of selected adjuvants used in antibody production. ILAR J 1995, 37(3):119-125.
46. Hernandez A., Yager J.A., Wilkie B.N., Leslie K.E., Mallard B.A. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants. Vet Immunol Immunopathol 2005, 104(March (1-2)):45-58.
47. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(May (19)):3752-3762.
48. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(October (5)):723-739.
49. Martin M., Michalek S.M., Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003, 71(May (5)):2498-2507.
50. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374(April (6522)):546-549.
51. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(December (6813)):740-745.
52. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3(August (8)):849-854.
53. Stacey K.J., Sweet M.J., Hume D.A. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996, 157(September (5)):2116-2122.
54. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188(December (12)):2335-2342.
55. Sparwasser T., Vabulas R.M., Villmow B., Lipford G.B., Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000, 30(December (12)):3591-3597.
56. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199(June):201-216.
57. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278(November (5343)):1626-1629.
58. Yu K.O., Im J.S., Molano A., Dutronc Y., Illarionov P.A., Forestier C., et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A 2005, 102(March (9)):3383-3388.
59. Goff R.D., Gao Y., Mattner J., Zhou D., Yin N., Cantu C., et al. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004, 126(October (42)):13602-13603.
60. Kim S., Lalani S., Parekh V.V., Wu L., Van Kaer L. Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev Vaccines 2008, 7(December (10)):1519-1532.
61. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007, 104(April (14)):6025-6030.
62. Torresi J., Fischer A., Grollo L., Zeng W., Drummer H., Jackson D.C. Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunol Cell Biol 2007, 85(February-March (2)):169-173.
63. Qiu Q., Wang R.Y., Jiao X., Jin B., Sugauchi F., Grandinetti T., et al. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 2008, 26(October (43)):5527-5534.
64. Stamataki Z., Coates S., Evans M.J., Wininger M., Crawford K., Dong C., et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007, 25(November (45)):7773-7784.
65. Qiao M., Murata K., Davis A.R., Jeong S.H., Liang T.J., Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 2003, 37(January (1)):52-59.
66. Hui G.S., Hashimoto C.N. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int Immunopharmacol 2008, 8(July (7)):1012-1022.
67. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173(September (5)):3148-3154.
68. Veldt B.J., van der Vliet H.J., von Blomberg B.M., van Vlierberghe H., Gerken G., Nishi N., et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 2007, 47(September (3)):356-365.
69. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 2007, 104(March (10)):3984-3989.
70. Myschik J., McBurney W.T., Hennessy T., Rades T., Hook S. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A. Pharmazie 2008, 63(September (9)):686-692.